NASDAQ:DRNADicerna Pharmaceuticals Stock Price, Forecast & News

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DRNA shares have increased by 52.1% and is now trading at $25.67. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) posted its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.28 by $0.59. The biopharmaceutical company earned $34.03 million during the quarter, compared to analyst estimates of $59.61 million. Dicerna Pharmaceuticals had a negative net margin of 213.04% and a negative return on equity of 74.79%. View Dicerna Pharmaceuticals' earnings history.

11 Wall Street analysts have issued 12 month price targets for Dicerna Pharmaceuticals' shares. Their forecasts range from $25.00 to $50.00. On average, they anticipate Dicerna Pharmaceuticals' share price to reach $34.20 in the next year. This suggests a possible upside of 33.2% from the stock's current price. View analysts' price targets for Dicerna Pharmaceuticals.

Press coverage about DRNA stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Dicerna Pharmaceuticals earned a coverage optimism score of -2.2 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View the latest news about Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 2,960,000 shares, a decrease of 7.8% from the June 15th total of 3,210,000 shares. Based on an average trading volume of 639,600 shares, the short-interest ratio is presently 4.6 days. Approximately 4.6% of the company's stock are short sold. View Dicerna Pharmaceuticals' Current Options Chain.

Some companies that are related to Dicerna Pharmaceuticals include Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), PPD (SDGR), United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Ultragenyx Pharmaceutical (RARE), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Emergent Biosolutions (EBS), Myokardia (MYOK), Blueprint Medicines (BPMC) and Nektar Therapeutics (NKTR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Amarin (AMRN), Strongbridge Biopharma (SBBP), Arbutus Biopharma (ABUS), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Exelixis (EXEL), ImmunoGen (IMGN) and Array Biopharma (ARRY).

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DRNA stock can currently be purchased for approximately $25.67.

Dicerna Pharmaceuticals has a market capitalization of $1.90 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe.

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]